Pacira BioSciences Reports Q1 2025 Financial Results with $168.9M Revenue

Pacira BioSciences, Inc. reported its financial results for the first quarter of 2025, revealing total revenues of $168.9 million, a slight increase from $167.1 million in the same period last year. The company's net product sales reached $167.6 million, up from $165.8 million in Q1 2024, driven primarily by a 3% increase in sales of its flagship product, EXPAREL, which generated $136.5 million. However, sales of ZILRETTA decreased by 10% to $23.3 million, attributed to a restructuring of the sales team that impacted promotional efforts. The company reported a net income of $4.8 million, down from $9.0 million in the prior year, resulting in a basic and diluted net income per share of $0.10.

In terms of operational changes, Pacira completed the acquisition of GQ Bio Therapeutics GmbH in February 2025, acquiring the remaining 81% equity interest for $30.3 million. This acquisition is expected to enhance the company's capabilities in gene therapy, particularly with its PCRX-201 product candidate, which is currently in a Phase 2 clinical trial for osteoarthritis of the knee. The company also reported a significant legal settlement of $7.0 million related to patent infringement suits, which was recorded as an expense in the current quarter.

The company’s total operating expenses increased to $166.9 million from $153.9 million in the previous year, largely due to higher selling, general, and administrative expenses, which rose by 20% to $86.8 million. This increase reflects investments in marketing and sales initiatives aimed at expanding the reach of its product portfolio. Research and development expenses also rose to $25.3 million, up 39% year-over-year, driven by costs associated with clinical trials for PCRX-201 and other product candidates.

As of March 31, 2025, Pacira reported cash and cash equivalents of $283.6 million, an increase from $276.8 million at the end of 2024. The company’s total assets grew to $1.59 billion, up from $1.55 billion, while total liabilities increased to $788.1 million from $775.2 million. The company’s accumulated deficit decreased to $201.5 million from $206.4 million, indicating a slight improvement in its financial position.

Looking ahead, Pacira aims to continue expanding the use of its products, particularly EXPAREL and ZILRETTA, while advancing its clinical pipeline, including the ongoing development of PCRX-201. The company is also focused on enhancing its manufacturing capabilities and exploring additional strategic investments to support its growth objectives.